Trial Profile
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2017
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Cyclophosphamide
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 01 Aug 2017 Results published in the American Journal of Clinical Oncology.
- 16 Feb 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 16 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.